-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the results of the third batch of centralized procurement of drugs in public medical institutions in Zhejiang Province were released
.
The data shows that the total sales scale of this collection and procurement varieties in public hospitals in Zhejiang Province in 2021 exceeded 300 million yuan (in terms of common names), involving bright prorelin injection, triptorelin injection, lactulose oral liquid and other large clinical varieties, Lizhu, Shisi Yao, Luoxin Pharmaceutical and other enterprises successfully broke through
.
.
The data shows that the total sales scale of this collection and procurement varieties in public hospitals in Zhejiang Province in 2021 exceeded 300 million yuan (in terms of common names), involving bright prorelin injection, triptorelin injection, lactulose oral liquid and other large clinical varieties, Lizhu, Shisi Yao, Luoxin Pharmaceutical and other enterprises successfully broke through
.
In September 2022, Zhejiang Provincial Pharmaceutical and Device Procurement Center issued the third batch of centralized procurement of drugs in public medical institutions in Zhejiang Province, and 22 varieties (including the first batch of unrenewed varieties) were included, of which 10 were digestive system and metabolic drugs, 3 were cardiovascular and cerebrovascular system drugs and systemic anti-infective drugs, and 2 were anti-tumor and immunomodulators and nervous system drugs
.
.
Zhejiang Province divides the varieties included in the procurement volume into group A (original research drugs or reference preparations, generic drugs that have passed the consistency evaluation) and group B (other generic drugs), that is, the "double envelope" mode, such as any group of flow labels in groups A and B, 50% of the agreed purchase volume of the group is merged into the agreed purchase volume of the other group, and the remaining 50% is used as the remaining amount
in addition to the agreed purchase quantity.
This is a positive signal
for both partially selected and unselected varieties.
in addition to the agreed purchase quantity.
This is a positive signal
for both partially selected and unselected varieties.
From the results of the proposed selection, piracetam sodium chloride injection and diflunisal oral regular-release dosage form are not among them, and the product quotation of amoxicillin clavulanate injection is too different from the original purchase price of the province, which needs to be further verified
.
The remaining varieties of enterprises to be selected will be announced in 2021, with a total sales scale of more than 300 million yuan (in terms of generic names)
in public hospitals in Zhejiang Province.
.
The remaining varieties of enterprises to be selected will be announced in 2021, with a total sales scale of more than 300 million yuan (in terms of generic names)
in public hospitals in Zhejiang Province.
Among them, there are many clinical varieties
such as leuprolide injection, triptorelin injection, lactulose oral liquid agent, reduced glutathione (glutathione) injection and so on.
such as leuprolide injection, triptorelin injection, lactulose oral liquid agent, reduced glutathione (glutathione) injection and so on.
Sales of leuprorelin injection in public hospitals in Zhejiang Province in recent years (: 10,000 yuan)
According to data from Minai.
com, the sales of bright prorelin injection in public hospitals in Zhejiang Province in 2021 exceeded 100 million yuan, and from the perspective of the competition pattern of manufacturers, Takeda dominated and Lizhu was closely behind
.
com, the sales of bright prorelin injection in public hospitals in Zhejiang Province in 2021 exceeded 100 million yuan, and from the perspective of the competition pattern of manufacturers, Takeda dominated and Lizhu was closely behind
.
In recent years, leuprorelin acetate microspheres (3.
75mg) for injection have won the bid
75mg) for injection have won the bid
Since 2022, the lowest winning bid price of leuprorelin acetate microspheres (3.
75mg) for injection has been 907.
13 yuan per unit, and the winning price of Lizhu in Zhejiang collective procurement is slightly lower than the lowest winning price
in 2022.
75mg) for injection has been 907.
13 yuan per unit, and the winning price of Lizhu in Zhejiang collective procurement is slightly lower than the lowest winning price
in 2022.
Drug sales in public hospitals in Zhejiang Province in recent years (: 100 million yuan)
At present, the centralized procurement of drugs at the provincial level has entered the normalization
.
Zhejiang Province has carried out the third batch
of drug procurement.
As more and more drugs are included in the centralized procurement, the public hospital market in Zhejiang Province will continue
to wave.
.
Zhejiang Province has carried out the third batch
of drug procurement.
As more and more drugs are included in the centralized procurement, the public hospital market in Zhejiang Province will continue
to wave.
List of selected varieties to be selected for the third batch of centralized procurement of drugs by public medical institutions in Zhejiang Province
Note: With * means that the agreed purchase quantity is 50% of the original agreed purchase quantity
Source: Minainet database, Zhejiang Provincial Drug and Equipment Procurement Center, etc
